Skip to main content

Drug Interactions between rifabutin and tivozanib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

rifabutin tivozanib

Applies to: rifabutin and tivozanib

GENERALLY AVOID: Coadministration of tivozanib with strong CYP450 3A4 inducers may decrease the plasma concentrations and therapeutic effects of tivozanib, which has been shown to be a substrate of the isoenzyme, When a single dose of tivozanib (1340 mcg) was administered to healthy volunteers with rifampin (600 mg daily; at steady-state), a strong CYP450 3A4 inducer, tivozanib systemic exposure (AUC) decreased by approximately one-half and its average half-life decreased from 121 to 54 hours, while peak plasma concentration (Cmax) did not change. The clinical effects of strong CYP450 3A4 inducers on repeated daily dosing of tivozanib has not been studied.

MANAGEMENT: Due to the potential for reduced anti-tumor activity, concomitant use of tivozanib with a strong CYP450 3A4 inducer should generally be avoided. If coadministration is necessary, some authorities advise caution, with clinical and laboratory monitoring to be considered whenever a strong CYP450 3A4 inducer is added to or withdrawn from therapy.

References (2)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. (2021) "Product Information. Fotivda (tivozanib)." Aveo Pharmaceuticals, Inc.

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer